Compare STRIDES PHARMA SCIENCE with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs SHASUN PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE SHASUN PHARMA STRIDES PHARMA SCIENCE/
SHASUN PHARMA
 
P/E (TTM) x 43.6 123.9 35.2% View Chart
P/BV x 2.0 8.5 23.9% View Chart
Dividend Yield % 0.2 0.2 102.4%  

Financials

 STRIDES PHARMA SCIENCE   SHASUN PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
SHASUN PHARMA
Mar-14
STRIDES PHARMA SCIENCE/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,14794 1,217.6%   
Low Rs64246 1,407.9%   
Sales per share (Unadj.) Rs317.2214.2 148.1%  
Earnings per share (Unadj.) Rs7.85.3 147.0%  
Cash flow per share (Unadj.) Rs25.115.8 158.4%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.21.4 15.6%  
Book value per share (Unadj.) Rs274.353.3 514.1%  
Shares outstanding (eoy) m89.5056.62 158.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.80.3 863.9%   
Avg P/E ratio x114.013.1 870.4%  
P/CF ratio (eoy) x35.74.4 808.0%  
Price / Book Value ratio x3.31.3 248.9%  
Dividend payout %25.518.7 136.0%   
Avg Mkt Cap Rs m80,0583,958 2,022.8%   
No. of employees `0002.5NA-   
Total wages/salary Rs m4,3412,164 200.6%   
Avg. sales/employee Rs Th11,325.8NM-  
Avg. wages/employee Rs Th1,731.4NM-  
Avg. net profit/employee Rs Th280.1NM-  
INCOME DATA
Net Sales Rs m28,39412,127 234.1%  
Other income Rs m941229 410.1%   
Total revenues Rs m29,33412,356 237.4%   
Gross profit Rs m3,9651,009 393.0%  
Depreciation Rs m1,540594 259.5%   
Interest Rs m1,962415 472.8%   
Profit before tax Rs m1,403230 610.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680 56,000.0%   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97-73 -133.8%   
Profit after tax Rs m702302 232.4%  
Gross profit margin %14.08.3 167.8%  
Effective tax rate %6.9-31.7 -21.9%   
Net profit margin %2.52.5 99.3%  
BALANCE SHEET DATA
Current assets Rs m24,8366,884 360.8%   
Current liabilities Rs m18,9938,456 224.6%   
Net working cap to sales %20.6-13.0 -158.8%  
Current ratio x1.30.8 160.6%  
Inventory Days Days7162 115.2%  
Debtors Days Days113108 105.4%  
Net fixed assets Rs m34,2894,970 689.9%   
Share capital Rs m895113 789.9%   
"Free" reserves Rs m23,6512,875 822.7%   
Net worth Rs m24,5463,020 812.7%   
Long term debt Rs m15,5131,817 853.6%   
Total assets Rs m65,43713,347 490.3%  
Interest coverage x1.71.6 110.4%   
Debt to equity ratio x0.60.6 105.0%  
Sales to assets ratio x0.40.9 47.8%   
Return on assets %4.15.4 75.8%  
Return on equity %2.910.0 28.6%  
Return on capital %6.913.3 51.7%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m15,6975,843 268.7%   
Fx outflow Rs m7352,173 33.8%   
Net fx Rs m14,9623,669 407.7%   
CASH FLOW
From Operations Rs m1,871398 470.5%  
From Investments Rs m5,826-1,635 -356.3%  
From Financial Activity Rs m-10,1571,309 -776.2%  
Net Cashflow Rs m-2,61571 -3,672.6%  

Share Holding

Indian Promoters % 27.7 39.2 70.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 3.6 1,050.0%  
FIIs % 8.6 17.6 48.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 39.6 65.4%  
Shareholders   56,241 20,750 271.0%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   CADILA HEALTHCARE  TTK HEALTHCARE  NEULAND LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Interglobe Aviation QIP, Rising Premium for Non-Life Insurers, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended lower yesterday. Benchmark indices ended nearly 1% lower, tracking weakness in global markets and dragged primarily by finance and banking stocks.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 11, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - DR. REDDYS LAB COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS